as 605240 profile

5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione: a PI3Kgamma inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione : A quinoxaline derivative that is quinoxaline in which the hydrogen at position 6 is replaced by a (2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl group. It is a potent inhibitor of the PI3Kgamma, with an IC50 of 8 nM and inhibits the progression of joint inflammation and damage in both lymphocyte-independent and dependent mouse models of rheumatoid arthritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	24906273
CHEMBL ID	3182407
SCHEMBL ID	668617
MeSH ID	M0491351
PubMed CID	5289247
CHEMBL ID	568150
CHEBI ID	45302
SCHEMBL ID	668616
MeSH ID	M0491351

Synonym
as-605240 ,
648450-29-7
HMS3265I22
5-(6-quinoxalinylmethylene)-2,4-thiazolidinedione
HMS3265J21
HMS3265I21
HMS3265J22
NCGC00186030-03
2,4-thiazolidinedione, 5-(6-quinoxalinylmethylene)-
SCHEMBL668617
SQWZFLMPDUSYGV-UHFFFAOYSA-N
CHEMBL3182407
AKOS026750391
Q27163228
5-(6-quinoxalinylmethylidene)thiazolidine-2,4-dione
5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
DTXSID101017269
SB19245
(5e)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
HMS3672M07
HMS3747K03
HY-10109
(5e)-5-(quinoxalin-6-ylmethylene)-1,3-thiazolidine-2,4-dione
5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione
qyt ,
2A5U
DB04769
NCGC00186030-01
HMS3229I19
CHEMBL568150 ,
(5z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
HMS3262N16
(z)-5-(quinoxalin-6-ylmethylene)thiazolidine-2,4-dione
bdbm50324735
as605240
BCP9000323
as 605240
CCG-101300
LP00947
CS-0084
S1410
BRD-K76773351-001-01-9
gtpl6023
pi 3-kg inhibitor
1287651-14-2
SCHEMBL668616
NCGC00261632-01
tox21_500947
5-(6-quinoxalinylmethylene)-2,4-thiazolidine-2,4-dione
AKOS024457698
HMS3650I15
J-516278
as605240, >=98% (hplc)
CHEBI:45302
5-[(quinoxalin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione
5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione
Q27088381
AS-16768
sr-02000000919
SR-02000000919-2
BCP02097
DTXSID401018492
(5z)-5-(6-quinoxalinylmethylene)-2,4-thiazolidinedione
SDCCGSBI-0086699.P002
NCGC00186030-13
(5z)-5-[(quinoxalin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione

Excerpt	Reference	Relevance
"Pretreatment with AS 605240 reduced these LPS-induced changes."	( PI3Kγ activation is required for LPS-induced reactive oxygen species generation in respiratory epithelial cells. Jeong, JS; Kim, DI; Kim, HJ; Kim, SR; Lee, YC; Park, JK, 2012)	0.7

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Role	Description
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	An inhibitor of phosphatidylinositol 3-kinase, EC 2.7.1.137, a family of related enzymes capable of phosphorylating the 3 position hydroxy group of the inositol ring of a phosphatidylinositol.
anti-inflammatory agent	Any compound that has anti-inflammatory effects.
antirheumatic drug	A drug used to treat rheumatoid arthritis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
quinoxaline derivative	Any naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
quinoxaline derivative	Any naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
thiazolidinediones	A thiadiazolidine in which the 1,3-thiazolidine ring is substituted by two oxo groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	11.0335	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	1.4125	0.1000	20.8793	79.4328	AID588453
ATAD5 protein, partial	Homo sapiens (human)	Potency	29.0810	0.0041	10.8903	31.5287	AID493106; AID493107
USP1 protein, partial	Homo sapiens (human)	Potency	89.1251	0.0316	37.5844	354.8130	AID504865
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	5.9728	0.5318	15.4358	37.6858	AID504845
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	21.1317	0.0015	30.6073	15,848.9004	AID1224821
Parkin	Homo sapiens (human)	Potency	4.6109	0.8199	14.8306	44.6684	AID720573
arylsulfatase A	Homo sapiens (human)	Potency	0.3013	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	10.0000	0.0355	20.9770	89.1251	AID504332
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	10.3225	0.0126	2.4518	25.0177	AID485313
ras-related protein Rab-9A	Homo sapiens (human)	Potency	3.2643	0.0002	2.6215	31.4954	AID485297
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	19.0975	0.0037	8.6189	23.2809	AID2660; AID2667; AID2668
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	14.6892	0.0037	8.1081	23.2809	AID2667
Ataxin-2	Homo sapiens (human)	Potency	1.9953	0.0119	12.2221	68.7989	AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Homo sapiens (human)	IC50 (µMol)	0.0080	0.0080	0.1290	0.2500	AID977608
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform	Homo sapiens (human)	IC50 (µMol)	0.0080	0.0080	0.1290	0.2500	AID977608
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	IC50 (µMol)	0.1876	0.0001	0.3371	7.3000	AID1534886; AID1799542
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	0.5369	10.0000	AID1284867
Casein kinase II subunit alpha'	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0003	1.4320	10.0000	AID1284865
Amine oxidase [flavin-containing] A	Homo sapiens (human)	IC50 (µMol)	165.8000	0.0000	2.3789	9.7700	AID612542
Amine oxidase [flavin-containing] B	Homo sapiens (human)	IC50 (µMol)	13.0000	0.0000	1.8914	9.5700	AID501302; AID612541
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	IC50 (µMol)	0.1396	0.0000	0.7340	10.0000	AID1534890; AID1799542
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	IC50 (µMol)	0.6676	0.0002	0.5953	10.0000	AID1534891; AID1799542
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	IC50 (µMol)	0.0947	0.0003	0.6607	10.0000	AID1231388; AID1284893; AID1534885; AID1799542
Dual specificity protein kinase CLK1	Homo sapiens (human)	IC50 (µMol)	0.0700	0.0074	0.4344	2.1000	AID1284866
Casein kinase II subunit beta	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0003	1.4875	10.0000	AID1284865
Casein kinase II subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0005	1.3332	10.0000	AID1284865
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)	IC50 (µMol)	0.8150	0.0031	0.7140	9.0120	AID1284862; AID1284956
Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)	IC50 (µMol)	0.1000	0.0140	0.9744	3.0000	AID1284864
CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)	IC50 (µMol)	3.2600	0.7310	3.7994	9.0780	AID616421
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)	IC50 (µMol)	0.0800	0.0010	0.5851	4.4200	AID1284863
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of epithelial tube formation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cell surface receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
MAPK cascade	Epidermal growth factor receptor	Homo sapiens (human)
ossification	Epidermal growth factor receptor	Homo sapiens (human)
embryonic placenta development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
hair follicle development	Epidermal growth factor receptor	Homo sapiens (human)
translation	Epidermal growth factor receptor	Homo sapiens (human)
signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
activation of phospholipase C activity	Epidermal growth factor receptor	Homo sapiens (human)
salivary gland morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
midgut development	Epidermal growth factor receptor	Homo sapiens (human)
learning or memory	Epidermal growth factor receptor	Homo sapiens (human)
circadian rhythm	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
diterpenoid metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
cerebral cortex cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell growth	Epidermal growth factor receptor	Homo sapiens (human)
lung development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of superoxide anion generation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
response to cobalamin	Epidermal growth factor receptor	Homo sapiens (human)
response to hydroxyisoflavone	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to reactive oxygen species	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of protein catabolic process	Epidermal growth factor receptor	Homo sapiens (human)
vasodilation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ovulation cycle	Epidermal growth factor receptor	Homo sapiens (human)
hydrogen peroxide metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
tongue development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA repair	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA replication	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of bone resorption	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Epidermal growth factor receptor	Homo sapiens (human)
regulation of JNK cascade	Epidermal growth factor receptor	Homo sapiens (human)
symbiont entry into host cell	Epidermal growth factor receptor	Homo sapiens (human)
protein autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
astrocyte activation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Epidermal growth factor receptor	Homo sapiens (human)
digestive tract morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
neuron projection morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
protein insertion into membrane	Epidermal growth factor receptor	Homo sapiens (human)
response to calcium ion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of glial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Epidermal growth factor receptor	Homo sapiens (human)
eyelid development in camera-type eye	Epidermal growth factor receptor	Homo sapiens (human)
response to UV-A	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of mucus secretion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to amino acid stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to cadmium ion	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to xenobiotic stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
liver regeneration	Epidermal growth factor receptor	Homo sapiens (human)
cell-cell adhesion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein kinase C activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of prolactin secretion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of cardiocyte differentiation	Epidermal growth factor receptor	Homo sapiens (human)
neurogenesis	Epidermal growth factor receptor	Homo sapiens (human)
multicellular organism development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
double-strand break repair	Casein kinase II subunit alpha'	Homo sapiens (human)
apoptotic process	Casein kinase II subunit alpha'	Homo sapiens (human)
spermatogenesis	Casein kinase II subunit alpha'	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit alpha'	Homo sapiens (human)
cerebral cortex development	Casein kinase II subunit alpha'	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit alpha'	Homo sapiens (human)
liver regeneration	Casein kinase II subunit alpha'	Homo sapiens (human)
regulation of mitophagy	Casein kinase II subunit alpha'	Homo sapiens (human)
positive regulation of protein targeting to mitochondrion	Casein kinase II subunit alpha'	Homo sapiens (human)
regulation of chromosome separation	Casein kinase II subunit alpha'	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Casein kinase II subunit alpha'	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit alpha'	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase II subunit alpha'	Homo sapiens (human)
biogenic amine metabolic process	Amine oxidase [flavin-containing] A	Homo sapiens (human)
positive regulation of signal transduction	Amine oxidase [flavin-containing] A	Homo sapiens (human)
dopamine catabolic process	Amine oxidase [flavin-containing] A	Homo sapiens (human)
response to xenobiotic stimulus	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to toxic substance	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to aluminum ion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to selenium ion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
negative regulation of serotonin secretion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
phenylethylamine catabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
substantia nigra development	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to lipopolysaccharide	Amine oxidase [flavin-containing] B	Homo sapiens (human)
dopamine catabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to ethanol	Amine oxidase [flavin-containing] B	Homo sapiens (human)
positive regulation of dopamine metabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to corticosterone	Amine oxidase [flavin-containing] B	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
liver development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vasculature development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
glucose metabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phagocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of lamellipodium assembly	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle inactivity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of macroautophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
actin cytoskeleton organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of actin filament depolymerization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell costimulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of TOR signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to insulin stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle stretch	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of multicellular organism growth	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to L-leucine	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cellular respiration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of neuron apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
relaxation of cardiac muscle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
adipose tissue development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to glucose stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to hydrostatic pressure	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to dexamethasone	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle cell contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
energy homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of actin filament organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
autosome genomic imprinting	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to butyrate	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of protein localization to membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cell-matrix adhesion	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
response to ischemia	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular calcium ion homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion molecules	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
embryonic cleavage	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of MAPK cascade	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
angiogenesis involved in wound healing	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of sprouting angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
regulation of clathrin-dependent endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
dendritic cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of acute inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of triglyceride catabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
secretory granule localization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of cell adhesion mediated by integrin	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of MAP kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cellular response to cAMP	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
hepatocyte apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of calcium ion transmembrane transport	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of RNA splicing	Dual specificity protein kinase CLK1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity protein kinase CLK1	Homo sapiens (human)
signal transduction	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of cell population proliferation	Casein kinase II subunit beta	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit beta	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit beta	Homo sapiens (human)
positive regulation of activin receptor signaling pathway	Casein kinase II subunit beta	Homo sapiens (human)
adiponectin-activated signaling pathway	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Casein kinase II subunit beta	Homo sapiens (human)
regulation of DNA binding	Casein kinase II subunit beta	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Casein kinase II subunit beta	Homo sapiens (human)
endothelial tube morphogenesis	Casein kinase II subunit beta	Homo sapiens (human)
protein-containing complex assembly	Casein kinase II subunit beta	Homo sapiens (human)
symbiont-mediated disruption of host cell PML body	Casein kinase II subunit beta	Homo sapiens (human)
negative regulation of viral life cycle	Casein kinase II subunit beta	Homo sapiens (human)
double-strand break repair	Casein kinase II subunit alpha	Homo sapiens (human)
protein phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
apoptotic process	Casein kinase II subunit alpha	Homo sapiens (human)
DNA damage response	Casein kinase II subunit alpha	Homo sapiens (human)
signal transduction	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of cell population proliferation	Casein kinase II subunit alpha	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of translation	Casein kinase II subunit alpha	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of Wnt signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of cell growth	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Casein kinase II subunit alpha	Homo sapiens (human)
rhythmic process	Casein kinase II subunit alpha	Homo sapiens (human)
protein stabilization	Casein kinase II subunit alpha	Homo sapiens (human)
chaperone-mediated protein folding	Casein kinase II subunit alpha	Homo sapiens (human)
symbiont-mediated disruption of host cell PML body	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of aggrephagy	Casein kinase II subunit alpha	Homo sapiens (human)
regulation of chromosome separation	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
regulation of cell cycle	Casein kinase II subunit alpha	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
chromatin remodeling	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nervous system development	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
circadian rhythm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-serine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-threonine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of microtubule polymerization	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of RNA splicing	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
amyloid-beta formation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-serine autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of mRNA splicing, via spliceosome	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of protein deacetylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
DNA damage response	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
smoothened signaling pathway	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
positive regulation of glycogen biosynthetic process	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
peptidyl-serine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
peptidyl-threonine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
regulation of autophagy	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
regulation of cellular respiration	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
protein maturation by [2Fe-2S] cluster transfer	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
DNA repair	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
myoblast fusion	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
adipose tissue development	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
peptidyl-serine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
peptidyl-threonine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha'	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha'	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
electron transfer activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
identical protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein kinase activator activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
identical protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ephrin receptor binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein binding	Dual specificity protein kinase CLK1	Homo sapiens (human)
ATP binding	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein serine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit beta	Homo sapiens (human)
chromatin binding	Casein kinase II subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit beta	Homo sapiens (human)
signaling receptor binding	Casein kinase II subunit beta	Homo sapiens (human)
protein binding	Casein kinase II subunit beta	Homo sapiens (human)
protein kinase regulator activity	Casein kinase II subunit beta	Homo sapiens (human)
protein domain specific binding	Casein kinase II subunit beta	Homo sapiens (human)
protein-macromolecule adaptor activity	Casein kinase II subunit beta	Homo sapiens (human)
identical protein binding	Casein kinase II subunit beta	Homo sapiens (human)
metal ion binding	Casein kinase II subunit beta	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Casein kinase II subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha	Homo sapiens (human)
kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
identical protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
Hsp90 protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
ATP binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
identical protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
tau protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
tau-protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
histone H3T45 kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
transcription coactivator activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
magnesium ion binding	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
ATP binding	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
manganese ion binding	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
protein serine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
pyridoxal phosphate binding	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
identical protein binding	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
protein homodimerization activity	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
metal ion binding	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
L-cysteine transaminase activity	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
2 iron, 2 sulfur cluster binding	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
transcription coactivator activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
ATP binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein serine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit alpha'	Homo sapiens (human)
acrosomal vesicle	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha'	Homo sapiens (human)
chromatin	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] A	Homo sapiens (human)
cytosol	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial envelope	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] B	Homo sapiens (human)
dendrite	Amine oxidase [flavin-containing] B	Homo sapiens (human)
neuronal cell body	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
intercalated disc	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
lamellipodium	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
nucleus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleolus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
midbody	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular membrane-bounded organelle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
nucleus	Dual specificity protein kinase CLK1	Homo sapiens (human)
plasma membrane	Casein kinase II subunit beta	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit beta	Homo sapiens (human)
PML body	Casein kinase II subunit beta	Homo sapiens (human)
extracellular region	Casein kinase II subunit beta	Homo sapiens (human)
nucleus	Casein kinase II subunit beta	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit beta	Homo sapiens (human)
cytoplasm	Casein kinase II subunit beta	Homo sapiens (human)
cytosol	Casein kinase II subunit beta	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit beta	Homo sapiens (human)
secretory granule lumen	Casein kinase II subunit beta	Homo sapiens (human)
extracellular exosome	Casein kinase II subunit beta	Homo sapiens (human)
ficolin-1-rich granule lumen	Casein kinase II subunit beta	Homo sapiens (human)
chromatin	Casein kinase II subunit beta	Homo sapiens (human)
cytoplasm	Casein kinase II subunit beta	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit alpha	Homo sapiens (human)
PML body	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
plasma membrane	Casein kinase II subunit alpha	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha	Homo sapiens (human)
Sin3-type complex	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
cytoskeleton	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
cytoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nuclear speck	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
axon	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
dendrite	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
ribonucleoprotein complex	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
nucleoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
cytoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
cytosol	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
ubiquitin ligase complex	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
ribonucleoprotein complex	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
cytoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
cytoskeleton	Dual specificity tyrosine-phosphorylation-regulated kinase 2	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
mitochondrion	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
mitochondrial outer membrane	CDGSH iron-sulfur domain-containing protein 1	Homo sapiens (human)
nucleoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
chromosome	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
nucleolus	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (100)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1799542	Kinase Assay from Article 10.1016/j.chembiol.2010.01.010: \\Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.\\	2010	Chemistry & biology, Feb-26, Volume: 17, Issue:2	Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347088	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347081	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347087	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1284862	Inhibition of recombinant human N-terminal His6-tagged DYRK1A catalytic domain expressed in Escherichia coli BL21(DE3) cells using KKISGRLSPIMTEQ-NH2 as substrate incubated for 15 mins in presence of [gamma-32P]ATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID444569	Effect on serum alanine aminotransaminase level in concanavalin A-induced acute hepatitis model of BALB/c mouse at 50 mg/kg, po treated 0.5 hrs after concanavalin A challenge measured after 20 hrs (Rvb= 5734.5 +/- 2599.5)	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice.
AID1284865	Inhibition of CK2 (unknown origin) using RRRDDDSDDD-NH2 as susbtrate incubated for 15 mins in presence of [gamma-32P]ATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID446227	Selectivity for PI3Kgamma over PI3Kbeta	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening.
AID719955	Antiarthritic activity in adjuvant-induced rheumatoid arthritis mouse model assessed as reduction in disease clinical score	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
AID1284864	Inhibition of recombinant human N-terminal GST-tagged DYRK2 expressed in Escherichia coli BL21(DE3) cells using KKISGRLSPIMTEQ-NH2 as substrate incubated for 15 mins in presence of [gamma-32P]ATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID1284867	Inhibition of EGFR (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID612542	Inhibition of human recombinant MAOA assessed as inhibition of kynuramine conversion to fluorescent metabolite 4-hydroxyquinoline by fluorimetry	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.
AID1534891	Inhibition of PI3Kbeta (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID1556586	Inhibition of MCP-1 mediated chemotaxis in mouse RAW264.7 cells at 20 uM measured after 3 hrs by light microscopic analysis relative to control	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis.
AID640769	Growth inhibition of rat C6 cells at 30 uM after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID640869	Inhibition of Erk1/2 activation in rat C6 cells at 30 uM after 30 mins by flow cytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID444567	Inhibition of MCP1-induced chemotaxis in mouse RAW264.7 cells at 25 ug/mL relative to control	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice.
AID1284868	Inhibition of PKCbeta (unknown origin) incubated for 15 mins in presence of [gamma-32P]ATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID1534885	Inhibition of PI3Kgamma (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID640766	Antiproliferative activity against human U138MG cells at 100 nM after 48 by hemocytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID444570	Effect on serum aspartate aminotransaminase level in concanavalin A-induced acute hepatitis model of BALB/c mouse at 50 mg/kg, po treated 0.5 hrs after concanavalin A challenge measured after 20 hrs (Rvb= 4997.9 +/- 2619.6)	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice.
AID1231388	Inhibition of human recombinant GST-tagged PI3Kgamma incubated for 180 mins using [33P]gamma-ATP by scintillation proximity assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions.
AID1284955	Growth inhibition of human U87MG cells after 4 days by MTT assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID444568	Inhibition of MCP1-induced chemotaxis in mouse RAW264.7 cells	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice.
AID1284863	Inhibition of full length recombinant human GST-tagged DYRK1B expressed in insect cells using KKISGRLSPIMTEQ-NH2 as substrate incubated for 15 mins in presence of [gamma-32P]ATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID640765	Cytotoxicity against rat C6 cells at 100 nM after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID446225	Selectivity for PI3Kgamma over PI3Kalpha	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening.
AID640770	Antiproliferative activity against human U138MG cells assessed as growth inhibition at 30 uM after 48 by hemocytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID1284866	Inhibition of recombinant human GST-tagged CLK1 catalytic domain (129 to 484 residues) expressed in Escherichia coli using GRSRSRSRSRSRSRSR as substrate incubated for 15 mins in presence of [gamma-32P]ATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID640768	Growth inhibition of human U138MG cells at 30 uM after 48 by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID640771	Antiproliferative activity against rat C6 cells assessed as growth inhibition at 30 uM after 48 hrs by hemocytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID640764	Cytotoxicity against human U138MG cells at 100 nM after 48 by MTT assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID1534890	Inhibition of PI3Kalpha (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID640868	Inhibition of Erk1/2 activation in rat C6 cells at 30 uM after 15 mins by flow cytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID1284893	Inhibition of human recombinant N-terminal GST-tagged PI3K-gamma (39 to 1102 residues) expressed n baculovirus infected TN5 cells using phosphatidylinositol as substrate by scintillation proximity assay in presence of {33P]gammaATP	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID501302	Inhibition of human recombinant MAO-B after 15 mins	2010	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17	Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.
AID640864	Inhibition of PI3Kgamma-mediated Akt activation in rat C6 cells at 30 uM after 15 mins by flow cytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID1284956	Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
AID612541	Inhibition of human recombinant MAOB by amplex red assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.
AID640865	Inhibition of PI3Kgamma-mediated Akt activation in rat C6 cells at 30 uM after 30 mins by flow cytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID616421	Displacement of [3H]-rosiglitazone from human recombinant C-terminal His-tagged cytosolic domain of mitoNEET (32-108) by scintillation proximity assay	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET.
AID1534886	Inhibition of PI3Kdelta (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID640767	Antiproliferative activity against rat C6 cells at 100 nM after 48 hrs by hemocytometric analysis	2012	European journal of medicinal chemistry, Feb, Volume: 48	Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation.
AID446226	Selectivity for PI3Kgamma over PI3Kdelta	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2005	Nature medicine, Sep, Volume: 11, Issue:9	Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1345749	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (Phosphatidylinositol kinases)	2005	Nature medicine, Sep, Volume: 11, Issue:9	Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
AID1345778	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (Phosphatidylinositol kinases)	2005	Nature medicine, Sep, Volume: 11, Issue:9	Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
AID1345786	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (Phosphatidylinositol kinases)	2005	Nature medicine, Sep, Volume: 11, Issue:9	Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
AID1345748	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (Phosphatidylinositol kinases)	2005	Nature medicine, Sep, Volume: 11, Issue:9	Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (14.61)	29.6817
2010's	65 (73.03)	24.3611
2020's	11 (12.36)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	4 (4.65%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
Other	82 (95.35%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.31	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.06	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.05	1	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostamide cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure	2.06	1	quinolines
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.47	2	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	4.67	8	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2.31	1	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.05	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	3.58	2	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	3.58	2	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	2.11	1	pilocarpine	antiglaucoma drug
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2.06	1	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	6.6	60	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.06	1	pyrrole; secondary amine
1,3-dithiane 1,3-dithiane: structure	2.21	1	dithiane
methoxyhydroxyphenylglycol Methoxyhydroxyphenylglycol: Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover.	2.06	1	methoxybenzenes; phenols
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2.06	1	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
allyl sulfide allyl sulfide: essence of garlic; inhibits CYP2E1	2.21	1	organic sulfide
n-propyl disulfide n-propyl disulfide: major flavor component of onions; non-nitrogenous, pungent volatile oil. dipropyl disulfide : An organic disulfide where the alkyl groups specified are propyl. It is a component of the essential oils obtained from Allium.	2.21	1	organic disulfide	plant metabolite
diallyl disulfide diallyl disulfide: major constituent of garlic oil. diallyl disulfide : An organic disulfide where the organic group specified is allyl. It has been isolated from garlic and other species of the genus Allium.	2.21	1	organic disulfide	antifungal agent; antineoplastic agent; plant metabolite
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.11	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.21	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.13	1	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	2.06	1	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.1	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
rosiglitazone [no description available]	3.58	2	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
3,4-dihydroxyphenylglycol 3,4-dihydroxyphenylglycol: noradrenaline metabolite in mouse brain; RN given refers to cpd without isomeric designation. 3,4-dihydroxyphenylethyleneglycol : A tetrol composed of ethyleneglycol having a 3,4-dihydroxyphenyl group at the 1-position.	2.06	1	catechols; tetrol	metabolite; mouse metabolite
n-acetylphenylalanine ethyl ester N-acetylphenylalanine ethyl ester: RN given refers to (L)-isomer	2.13	1
p-methoxy-n-methylphenethylamine p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.	2.11	1	aromatic ether; secondary amino compound	metabolite
rc 3095 bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-: an antagonist of bombesin	2.11	1
methotrexate [no description available]	2.11	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.17	1	amino acid zwitterion; angiotensin II	human metabolite
wortmannin [no description available]	4.1	4	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.06	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
4,5-dimethylaminobenzylidene-2-thiobarbituric acid [no description available]	2.05	1
3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione 3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione: inhibits ERK1 and ERK2; structure in first source	2.46	2
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.11	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
4-hydroxyphenylmethylene hydantoin 4-hydroxyphenylmethylene hydantoin: isoalted from the Red Sea sponge Hemimycale arabica; structure in first source	2.05	1
5-[[(5,6-dimethyl-4-thieno[2,3-d]pyrimidinyl)thio]methyl]-2-furancarboxylic acid methyl ester [no description available]	2.05	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound; thienopyrimidine
sb 225002 [no description available]	2.21	1	nitrophenol
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	3.31	1	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.13	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
as 604850 [no description available]	2.02	1
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.06	1
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.06	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.	2.21	1	chalcogen; nonmetal atom	macronutrient
5-(4-methoxybenzylidene)thiazolidine-2,4-dione 5-(4-methoxybenzylidene)thiazolidine-2,4-dione: used to treat concanavalin A-induced liver injury; structure in first source	2.05	1
su 1498 SU 1498: structure in first source. SU1498 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enoic acid with the amino group of 3-phenylpropylamine.	2.06	1	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist
lobeglitazone lobeglitazone: putative antidiabetic agent for type 2 diabetes; structure in first source	3.21	1	aromatic ether
pd 176252 PD 176252: a non-peptide gastrin-releasing peptide (BB2) receptor antagonist; structure in first source	2.11	1
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.07	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	3.87	3	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
ic 87114 IC 87114: structure in first source	3.17	1	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
ly-2157299 LY-2157299: an orally active transforming growth factor beta receptor (TGF-beraR) kinase inhibitor. LY-2157299 : A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma.	3.31	1	aromatic amide; methylpyridines; monocarboxylic acid amide; pyrrolopyrazole; quinolines	antineoplastic agent; TGFbeta receptor antagonist
pik 75 PIK 75: structure in first source	2.11	1
sd-208 [no description available]	3.31	1
tg100-115 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol: for treatment of ischemia reperfusion injury; structure in first source	4.13	2	pteridines
5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione 5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione: a PI3Kgamma inhibitor; structure in first source	4.36	3
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	4.44	3	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	3.31	1	pyrazolopyrimidine
zstk474 ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.	3.61	2	benzimidazoles; morpholines; organofluorine compound; triamino-1,3,5-triazine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
in 1130 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide: an activin receptor-like kinase-5 inhibitor; structure in first source	3.31	1
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	3.17	1	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
bms 777607 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source	3.31	1	aromatic amide
sgi 1776 SGI 1776: a Pim kinase inhibitor; structure in first source	3.31	1	imidazoles
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.17	1	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	2.05	1
mk-8033 1-(3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide: inhibits both Ron and c-Met kinases; structure in first source	3.31	1
gsk2269557 Nemiralisib: PI3K delta - selective inhibitor	3.17	1
ipi-145 [no description available]	3.69	2	isoquinolines
ew-7197 vactosertib: a TGF-beta type I receptor kinase inhibitor with antifibrotic and antineoplastic activities; structure in first source	3.31	1
gastrin-releasing peptide Gastrin-Releasing Peptide: Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.	2.11	1
azd1208 [no description available]	3.31	1
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.06	1
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.05	1
antimony sodium gluconate Antimony Sodium Gluconate: Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.	2.07	1

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.66	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.54	22
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.66	2
Rheumatoid Arthritis [description not available]	3.64	3
Primary Peritonitis [description not available]	2.02	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	3.64	3
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	2.02	1
Acute Liver Injury, Drug-Induced [description not available]	2.78	3
Acute Hepatic Failure [description not available]	2.05	1
Liver Failure, Acute A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.	2.05	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.78	3
Benign Neoplasms, Brain [description not available]	2.07	1
Glial Cell Tumors [description not available]	2.07	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.07	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.07	1
Autoimmune Disease [description not available]	3.65	3
Innate Inflammatory Response [description not available]	4.98	8
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	3.65	3
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	4.98	8
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Benign Neoplasms [description not available]	3.12	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.12	1
Hepatitis INFLAMMATION of the LIVER.	2.21	1
Contact Dermatitis [description not available]	2.21	1
Itching [description not available]	2.8	3
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	2.21	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.8	3
Lung Injury, Acute [description not available]	2.8	3
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.8	3
Bone Loss, Osteoclastic [description not available]	2.6	1
Age-Related Osteoporosis [description not available]	2.6	1
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.6	1
Alveolitis, Fibrosing [description not available]	2.51	2
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.51	2
Cardio-embolic Stroke [description not available]	2.25	1
Blood Poisoning [description not available]	2.54	2
Cardiomyopathies, Primary [description not available]	2.15	1
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	2.15	1
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	2.54	2
Acute Lymphoid Leukemia [description not available]	2.17	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.17	1
Carcinoma, Epidermoid [description not available]	2.15	1
Cancer of Mouth [description not available]	2.15	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.15	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.15	1
Cardiac Toxicity [description not available]	2.17	1
Breast Cancer [description not available]	2.17	1
Cardiac Diseases [description not available]	2.17	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.17	1
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.17	1
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	2.17	1
Cardiomyopathy, Chagas [description not available]	2.17	1
Chagas Cardiomyopathy A disease of the CARDIAC MUSCLE developed subsequent to the initial protozoan infection by TRYPANOSOMA CRUZI. After infection, less than 10% develop acute illness such as MYOCARDITIS (mostly in children). The disease then enters a latent phase without clinical symptoms until about 20 years later. Myocardial symptoms of advanced CHAGAS DISEASE include conduction defects (HEART BLOCK) and CARDIOMEGALY.	2.17	1
Chronic Kidney Diseases [description not available]	2.17	1
Cirrhosis [description not available]	2.51	2
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.51	2
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	2.17	1
Brain Emboli [description not available]	2.21	1
Brain Hemorrhage, Cerebral [description not available]	2.21	1
Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	2.21	1
Peripheral Nerve Diseases [description not available]	2.21	1
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	2.21	1
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.21	1
Apoplexy [description not available]	2.21	1
Cerebral Ischemia [description not available]	2.21	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.21	1
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.21	1
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.21	1
Congestive Ophthalmopathy [description not available]	2.1	1
Graves Ophthalmopathy An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.	2.1	1
Libman-Sacks Disease [description not available]	2.73	3
Glomerulonephritis, Lupus [description not available]	2.46	2
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	2.73	3
Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).	2.46	2
Carotid Arteriopathies, Traumatic [description not available]	2.1	1
Neointima The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.	2.1	1
Absence Seizure [description not available]	2.11	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.11	1
Cerebral Malaria [description not available]	2.11	1
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	2.11	1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	2.11	1
Airflow Obstruction, Chronic [description not available]	2.11	1
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	2.11	1
Capillary Leak Syndrome A condition characterized by recurring episodes of fluid leaking from capillaries into extra-vascular compartments causing hematocrit to rise precipitously. If not treated, generalized vascular leak can lead to generalized EDEMA; SHOCK; cardiovascular collapse; and MULTIPLE ORGAN FAILURE.	2.13	1
Edema, Pulmonary [description not available]	2.13	1
Acute Respiratory Distress Syndrome [description not available]	2.13	1
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	2.13	1
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	2.13	1
Autoimmune Diabetes [description not available]	2.51	2
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.51	2
Cirrhosis, Liver [description not available]	2.05	1
Acute Disease Disease having a short and relatively severe course.	2.46	2
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.05	1
Adenoma, beta-Cell [description not available]	2.05	1
Cancer of Pancreas [description not available]	2.05	1
Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.	2.05	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.05	1
Chronic Illness [description not available]	2.05	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.05	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.46	2
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	2.05	1
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	2.05	1
Carditis [description not available]	2.05	1
Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.	2.05	1
Cardiovascular Stroke [description not available]	2.75	3
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.75	3
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.05	1
Cardiac Remodeling, Ventricular [description not available]	2.46	2
Acquired Immune Deficiency Syndrome [description not available]	2.06	1
Kaposi Sarcoma [description not available]	2.06	1
Cancer of Skin [description not available]	2.06	1
Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	2.06	1
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	2.06	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.06	1
Insulin Sensitivity [description not available]	2.06	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.06	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.06	1
Cardiac Failure [description not available]	2.06	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.06	1
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	2.06	1
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	2.06	1
Nerve Pain [description not available]	2.06	1
Neuritis A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include PAIN; PARESTHESIAS; PARESIS; or HYPESTHESIA.	2.06	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.06	1
Blood Pressure, High [description not available]	2.07	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.07	1
Disease Resistance The capacity of an organism to defend itself against pathological processes or the agents of those processes. This most often involves innate immunity whereby the organism responds to pathogens in a generic way. The term disease resistance is used most frequently when referring to plants.	2.07	1
Leishmaniasis, American [description not available]	2.07	1
Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	2.07	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.07	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.07	1
Allergic Encephalomyelitis [description not available]	2.07	1
Polyarthritis [description not available]	2.02	1
Arthritis Acute or chronic inflammation of JOINTS.	2.02	1
Pneumonia, Pneumococcal A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.	2.03	1
Atherogenesis [description not available]	2.04	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.04	1

as 605240

Description

Cross-References

Synonyms (66)

Research Excerpts

Treatment

Bioavailability

Roles (3)

Drug Classes (2)

Protein Targets (31)

Potency Measurements

Inhibition Measurements

Biological Processes (275)

Molecular Functions (62)

Ceullar Components (60)

Bioassays (100)

Research

Studies (89)

Market Indicators

Research Demand Index: 17.94

Study Types

as 605240

Description

Cross-References

Synonyms (66)

Research Excerpts

Treatment

Bioavailability

Roles (3)

Drug Classes (2)

Protein Targets (31)

Potency Measurements

Inhibition Measurements

Biological Processes (275)

Molecular Functions (62)

Ceullar Components (60)

Bioassays (100)

Research

Studies (89)

Market Indicators

Research Demand Index: 17.94

Study Types

Related Drugs (76)

Related Conditions (138)